Lutetium-(177Lu)-oxodotreotide: Myeloid neoplasm.
In: Reactions Weekly, Jg. 1998 (2024-03-09), Heft 1, S. 291-291
serialPeriodical
Zugriff:
A study involving 27 patients with advanced neuroendocrine tumors (NET) and bone metastases found that one patient developed therapy-related myeloid neoplasm (t-MN) after receiving lutetium-(177Lu)-oxodotreotide treatment. The patient's age, sex, and specific treatment details were not provided. The patient was enrolled in the study and initiated on peptide receptor radionuclide therapy (PRRT) using lutetium-(177Lu)-oxodotreotide. However, the patient developed t-MN as a result of the treatment, although the timing of the reaction and the outcome were not mentioned. [Extracted from the article]
Titel: |
Lutetium-(177Lu)-oxodotreotide: Myeloid neoplasm.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 1998 (2024-03-09), Heft 1, S. 291-291 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-024-54135-9 |
Schlagwort: |
|
Sonstiges: |
|